<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779554</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20-GI-115</org_study_id>
    <nct_id>NCT04779554</nct_id>
  </id_info>
  <brief_title>Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC</brief_title>
  <official_title>A Randomized Phase 2 Trial of Flat Dose vs. Weight-based Dose of Intra-peritoneal (IP) Chemotherapy for Patients Undergoing Cytoreductive Surgery and Heated Intra-peritoneal Chemotherapy (CRS/HIPEC) for Advanced Gastrointestinal Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prakash Pandalai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been&#xD;
      associated with poor overall survival (â‰¤ 12 months) with few treatment options. Cytoreductive&#xD;
      surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct&#xD;
      administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected&#xD;
      peritoneal surfaces, has been shown to be an effective treatment option that extends overall&#xD;
      survival among certain cases of peritoneal carcinomatosis. IP chemotherapy allows delivery of&#xD;
      a high dose of cytostatic drug directly onto the peritoneal surfaces at risk for microscopic&#xD;
      residual disease while systemic exposure remains limited. Additionally, hyperthermia is known&#xD;
      to enhance the cytotoxicity of several agents (including Mitomycin C) and improves the depth&#xD;
      of peritoneal penetration.&#xD;
&#xD;
      This trial will be a randomized phase 2 comparison of flat dose versus weight-based dose&#xD;
      Mitomycin C. The hypothesis of this study is that HIPEC weight-based dosing may result in&#xD;
      similarly effective peritoneal Mitomycin C concentrations with less systemic absorption and&#xD;
      potential systemic toxicity, compared with the HIPEC flat dosing approach in patients&#xD;
      undergoing CRS/HIPEC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) - Pharmacokinetics</measure>
    <time_frame>Approximately 20 hours</time_frame>
    <description>Drug exposure will be measured by calculating the area under the curve (AUC) or integral of a plasma concentration-time curve. Samples will be collected at 0,15, 30, 60 and 90 minutes intra-operatively, and 2, 4, and 12 hours postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Clearance (CL) - Pharmacokinetics</measure>
    <time_frame>Approximately 20 hours</time_frame>
    <description>Drug clearance will be calculated as the volume of plasma cleared per unit time. Samples will be collected at 0,15, 30, 60 and 90 minutes intra-operatively, and 2, 4, and 12 hours postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Half-Life (T1/2) - Pharmacokinetics</measure>
    <time_frame>Approximately 20 hours</time_frame>
    <description>Drug half-life will be calculated as the time required for the plasma Mitomycin C concentration to be half of its maximum concentration. Samples will be collected at 0,15, 30, 60 and 90 minutes intra-operatively, and 2, 4, and 12 hours postoperatively.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Flat Dose Mitomycin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weight-Based Mitomycin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C, flat dose 40 mg</intervention_name>
    <description>Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.</description>
    <arm_group_label>Flat Dose Mitomycin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C, weight-based dose 12.5 mg/m2</intervention_name>
    <description>Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.</description>
    <arm_group_label>Weight-Based Mitomycin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with one of the following: low-grade appendiceal mucinous neoplasm,&#xD;
             appendiceal cancer with peritoneal carcinomatosis, colorectal cancer with peritoneal&#xD;
             carcinomatosis&#xD;
&#xD;
          -  ECOG performance status &lt; 3&#xD;
&#xD;
          -  Candidate for grossly complete cytoreductive surgery&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any extra-abdominal metastases&#xD;
&#xD;
          -  Untreated lung metastases&#xD;
&#xD;
          -  Liver metastases not amenable to resection or ablation&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 4 weeks prior to entering the study&#xD;
&#xD;
          -  Presence of residual significant adverse events attributed to prior cancer treatment&#xD;
&#xD;
          -  Currently receiving any other investigational therapeutic agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Mitomycin C.&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Uncontrolled ongoing illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Pandalai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prakash Pandalai, MD</last_name>
    <phone>859-323-8920</phone>
    <email>Prakash.Pandalai@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prakash Pandalai, MD</last_name>
      <email>Prakash.Pandalai@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Prakash Pandalai</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cytoreductive surgery</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>pseudomyxoma peritonei</keyword>
  <keyword>appendiceal mucinous neoplasm</keyword>
  <keyword>mitomycin C</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>CRS/HIPEC</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Appendix cancer</keyword>
  <keyword>LAMN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

